Localized Prostate Cancer
Advertisement
Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative.
Utilizing BCR as a replacement measurement for OS in patients with localized prostate cancer is a controversial topic.
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
What role can artificial intelligence play in the diagnosis and management of prostate cancer utilizing MRI?
An AI-based model predicts which patients with localized prostate cancer would better benefit from the use of ADT.
Dr. Brian Helfand details the purpose of 18F-rhPSMA-7.3 and how it compares to other PSMA PET radiopharmaceuticals.
Dr. Miron provides an overview of clinical implications of molecular alterations in intraductal carcinoma of the prostate.
Drs. Armstrong and Wallis discuss the design of an AI-derived pathology-based biomarker for localized high-risk prostate.
The postsurgical treatment of functional outcomes such as UI and ED after SRP remains a challenge for all urologists.
PSA nadir ≥0.1 ng/mL within 6 months of RT completion may be prognostic for long-term outcomes in patients receiving ...
Adherence to the National Comprehensive Cancer Network clinical practice guidelines may lead to better outcomes for patients.
The recent ProtecT analysis examined 15-year follow-up data on mortality, metastasis-free survival, and disease progression.
Transcriptomic profiling was used to identify predictive biomarkers and determine patient response to docetaxel therapies.
A study arm from the phase 3 EMBARK trial evaluating enzalutamide for nmCSPC with high-risk BCR has had positive outcomes.
A recent study analyzed a 15-year follow-up in men with prostate cancer to gauge the effectiveness of different treatments.
This review highlights the research on the costs related to the treatment of localized PC and the associated outcomes.
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
David Nanus, MD, details the ways in which PSMA PET varies in guidelines and is used to stage localized prostate cancer.
A recent update on the phase 3 MIRAGE trial determined if MRI or CT-guided stereotactic body radiotherapy is most effective.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.